International clinical guidelines for the management of phosphomannomutase 2‐congenital disorders of glycosylation: diagnosis, treatment and follow up

R Altassan, R Péanne, J Jaeken… - Journal of inherited …, 2019 - Wiley Online Library
Phosphomannomutase 2 (PMM2‐CDG) is the most common congenital disorder of N‐glycosylation
and is caused by a deficient PMM2 activity. The clinical presentation and the onset …

Consensus guideline for the diagnosis and management of mannose phosphate isomerase‐congenital disorder of glycosylation

A Čechová, R Altassan, D Borgel… - Journal of inherited …, 2020 - Wiley Online Library
Mannose phosphate isomerase‐congenital disorder of glycosylation (MPI‐CDG) deficiency
is a rare subtype of congenital disorders of protein N‐glycosylation. It is characterised by …

International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1‐CDG): diagnosis, follow‐up, and management

R Altassan, S Radenkovic… - Journal of inherited …, 2021 - Wiley Online Library
Ruqaiah Altassan and Silvia Radenkovic equally contributed in this work. … Ruqaiah Altassan
designed the work, collected the literature in a shred folder for the teams, coordinated the …

[PDF][PDF] The metabolic map into the pathomechanism and treatment of PGM1-CDG

…, J Verheijen, P Witters, R Altassan… - The American Journal of …, 2019 - cell.com
Phosphoglucomutase 1 (PGM1) encodes the metabolic enzyme that interconverts glucose-6-P
and glucose-1-P. Mutations in PGM1 cause impairment in glycogen metabolism and …

[HTML][HTML] Long-term follow-up in PMM2-CDG: are we ready to start treatment trials?

P Witters, T Honzik, E Bauchart, R Altassan… - Genetics in …, 2019 - Elsevier
Purpose PMM2-CDG is the most common congenital disorder of glycosylation (CDG), which
presents with either a neurologic or multisystem phenotype. Little is known about the …

Clinical, biochemical, and molecular overview of transaldolase deficiency and evaluation of the endocrine function: Update of 34 patients

…, V Valayannopoulos, R Altassan… - Journal of inherited …, 2019 - Wiley Online Library
Background Transaldolase deficiency (TALDO‐D) is a rare autosomal recessive inborn error
of the pentose phosphate pathway. Since its first description in 2001, several case reports …

[HTML][HTML] New insights into immunological involvement in congenital disorders of glycosylation (CDG) from a people-centric approach

…, S Brasil, FM Pimentel-Santos, R Altassan… - Journal of Clinical …, 2020 - mdpi.com
Congenital disorders of glycosylation (CDG) are rare diseases with variable phenotypes and
severity. Immunological involvement remains a largely uncharted topic in CDG, mainly due …

AAV-based gene therapy prevents and halts the progression of dilated cardiomyopathy in a mouse model of phosphoglucomutase 1 deficiency (PGM1-CDG)

B Balakrishnan, R Altassan, R Budhraja, W Liou… - Translational …, 2023 - Elsevier
… Author links open overlay panel Bijina Balakrishnan 1 # , Ruqaiah Altassan 2 # , Rohit
Budhraja 3 , Willisa Liou 4 , Arielle Lupo 1 , Sarah Bryant 1 , Anastasiya Mankouski 5 , Silvia …

Exome sequencing identifies novel NTRK1 mutations in patients with HSAN‐IV phenotype

R Altassan, HA Saud, TA Masoodi… - American Journal of …, 2017 - Wiley Online Library
Hereditary sensory autonomic neuropathy type IV (HSAN‐IV) is a rare autosomal recessive
disorder that usually begins in infancy and is characterized by anhidrosis, insensitivity to …

Neurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow …

…, JM Perez-Ortiz, AN Ligezka, R Altassan… - Genetics in …, 2024 - Elsevier
Purpose In the absence of prospective data on neurological symptoms, disease outcome, or
guidelines for system specific management in phosphomannomutase 2-congenital …